ALX Oncology reports positive interim Phase 2 ASPEN-06 data for evorpacept in HER2+ gastric cancer

ALX ONCOLOGY HOLDINGS INC

Confirmed ORR 52% for evorpacept combo vs 22% control; median DOR not reached vs 7.4 months.
First positive randomized data for any CD47 blocker in solid tumors; safety consistent with prior trials.
Phase 3 ASPEN-06 initiation planned late 2024; final Phase 2 results expected Q2 2024.
Stratification factors (2nd/3rd line, prior ENHERTU) prespecified and balanced per protocol.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.